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Abstract
Background: Endophenotypes are heritable markers, which are more prevalent in patients and
their healthy relatives than in the general population. Recent studies point at disturbed regulation
of the hypothalamic-pituitary-adrenocortical axis as a possible endophenotype for depression. We
hypothesize that potential endophenotypes for depression may be affected by selective serotonin
re-uptake inhibitor antidepressants in healthy first-degree relatives of depressed patients. The
primary outcome measure is the change in plasma cortisol in the dexamethasone-corticotrophin
releasing hormone test from baseline to the end of intervention.
Methods: The AGENDA trial is designed as a participant, investigator, observer, and data-analyst-
blinded randomized trial. Participants are 80 healthy first-degree relatives of patients with
depression. Participants are randomized to escitalopram 10 mg per day versus placebo for four
weeks. Randomization is stratified by gender and age. The primary outcome measure is the change
in plasma cortisol in the dexamethasone-corticotrophin releasing hormone test at entry before
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Trials 2009, 10:66 http://www.trialsjournal.com/content/10/1/66intervention to after four weeks of intervention. With the inclusion of 80 participants, a 60% power
is obtained to detect a clinically relevant difference in the primary outcome between the
intervention and the placebo group. Secondary outcome measures are changes from baseline to
four weeks in scores of: 1) cognition and 2) neuroticism. Tertiary outcomes measures are changes
from baseline to four weeks in scores of: 1) depression and anxiety symptoms; 2) subjective
evaluations of depressive symptoms, perceived stress, quality of life, aggression, sleep, and pain; and
3) salivary cortisol at eight different timepoints during an ordinary day. Assessments are undertaken
by assessors blinded to the randomization group.
Trial registration: Local Ethics Committee: H-KF 307413
Danish Medicines Agency: 2612-3162.
EudraCT: 2006-001750-28.
Danish Data Agency: 2006-41-6737.
ClinicalTrials.gov: NCT 00386841
Background
Robins and Guze described five phases in the develop-
ment of a valid classification of psychiatric illness: clinical
description, laboratory studies, delimitation from other
disorders, follow-up studies and family studies [1]. Later,
response to treatment was added as a sixth phase [2].
Recently, the endophenotype concept has emerged as a
strategic tool in neuropsychiatric research [3].
Endophenotypes are quantifiable components in the
"genes-to-behaviours" pathways distinct from psychiatric
symptoms [3]. In parallel with the classification of psychi-
atric diseases, endophenotypes are validated by specifi-
city, state independence, heritability, familial association,
co-segregation, and biological and clinically plausibility
[4].
Several possible endophenotypes have been proposed in
affective disorders, including stress regulation, cognition,
neuroticism, depression and anxiety symptoms [4]. Phar-
macological anti-depressants may have an effect on endo-
phenotypes in healthy persons with a family history of
depression. We hypothesized that treatment response
could be added to the validation of possible endopheno-
types for depression. However, a systematic search for ran-
domized multiple-dose, placebo-controlled trials on the
effect of selective serotonin reuptake inhibitors did not
identify any trials in which healthy first-degree relatives of
depressed patients received a selective serotonin re-uptake
inhibitor for at least one week (unpublished data).
Possible endophenotypes for depression
Hypothalamus-pituitary-adreno-cortical (HPA) axis regulation
Impaired regulation of the HPA axis during an acute epi-
sode of depression is the most consistent laboratory find-
ing [5-7]. The combined dexamethasone (DEX)-
corticotrophine releasing hormone (CRH) test is a sensi-
tive test for detecting altered HPA axis regulation [8]. In
this test, the stimulating effects of 100 μg CRH on cortico-
trophin (ACTH) and cortisol are examined under the sup-
pressive action of 1.5 mg of dexamethasone. ACTH and
cortisol in the combined DEX-CRH test demonstrated an
exaggerated response in patients with depression com-
pared to healthy controls with a family history of depres-
sion [9] and between healthy first-degree relatives of
patients with depression compared to healthy controls
without a family history of depression [9]. Increased
ACTH and cortisol in the combined DEX-CRH test there-
fore seems to be a promising biomarker for depression
and a potential endophenotype for depression [10].
Cognition
Alterations in cognitive functions are common and
included in the diagnostic criteria for depression [11] and
some patients experience cognitive dysfunction even in
euthymic phases of the disease [12-16]. A high-risk study
showed impairment of selective and sustained attention,
executive function, language processing and working and
declarative memory in subjects with a family history of
depression as compared to participants without [17].
Thus cognitive function may be a candidate endopheno-
type for affective disorders.
Personality
Neuroticism is a measure of an individual's tendency to
experience negative emotions that are manifested at one
extreme as anxiety, depression, and moodiness, and at
another extreme, as emotional stability. Neuroticism is
most frequently measured by questionnaires such as
Eysenck Personality Questionnaire (EPQ) [18] and the
revised NEO Personality Inventory (NEO-PI-R) [19]. The
heritability of neuroticism is well established [20]. StudiesPage 2 of 11
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sion point at neuroticism as an endophenotype for
depression [21].
Other potential endophenotypes for depression
More than 90% of depressed patients complain about
impairment of sleep quality, which has been suggested as
a potential endophenotype for depression [22]. The effect
of antidepressants on sleep quality in healthy individuals
with a family history of depression has not been investi-
gated. Subjective measures of stress, aggression, pain, and
quality of life are all factors known to improve with remis-
sion of depressive symptoms. Whether this is a direct
effect of treatment with antidepressants or a consequence
of improvement in depressive symptoms is unclear.
Proportion of possible endophenotypes for depression
Based on results from recent studies it is estimated that
30% of healthy persons with a family history of depres-
sion will exhibit at least two of the three possible endo-
phenotypes: dysregulation of the HPA axis, cognition, and
neuroticism [23]. The prevalence of other possible endo-
phenotypes is unknown.
The effect of antidepressants on endophenotypes for 
depression
Treatment with antidepressants in patients with an acute
depression is associated with partial normalization of the
HPA axis [24,25], enhanced cognitive function [26], and
reduction in the personality trait of neuroticism [27]. In
these trials it has not been possible to distinguish the
treatment effect on the endophenotypes from the treat-
ment effect on the disease, since remission of depressive
symptoms is associated with partial normalization of the
endophenotypes. It is not known whether the treatment
responses on the disease symptoms are mediated through
an effect on the endophenotypes or vice versa. Results of
recent randomized, placebo-controlled trials suggest that
antidepressants have an effect on psychological variables
and behaviour in individuals without psychiatric illness
[28-30], one of these studies did not mention the family
history status of the included individuals [28] but in two
of the studies [29,30] healthy individuals with a family
history of psychiatric illness were excluded.
In summary, no trial has investigated the effects of antide-
pressants on possible endophenotypes in healthy individ-
uals with a family history of depression.
Genotyping
A recent systematic review and meta-analysis of pharma-
cogenetic studies of antidepressant response suggests that
polymorphisms in genes such as 5-HTTLPR, STin2,
HTR1A, HTR2A, TPH1, and BDNF may modulate antide-
pressant response [31], but the association between gene
polymorphisms and the effect of an antidepressant treat-
ment on the putative endophenotypes for depression has
not been explored.
Objectives
With the AGENDA trial (Associations between Gene-pol-
ymorphisms, Endophenotypes for Depression and Anti-
depressive Intervention) we want to test the hypothesis
that potential endophenotypes for depression are affected
by intervention with an antidepressant in healthy first-
degree relatives of patients with the diagnosis of depres-
sion.
Methods
The AGENDA trial is designed as a participant, investiga-
tor, observer, and data-analyst-blinded randomized trial
in which participants receive either escitalopram 10 mg or
placebo for a period of four weeks (Figure 1).
Study organization
The study is conducted at the Department of Psychiatry,
Rigshospitalet, Copenhagen University Hospital, Den-
mark as part of the Centre for Pharmacogenomics, Uni-
versity of Copenhagen. The trial has a data monitoring
and safety committee (DMSC) that is independent of the
investigators conducting the trial.
Participants
Participants are recruited as healthy first-degree relatives
of patients with a diagnosis of depression given at dis-
charge from psychiatric hospital in- or out-patient contact
[32]. These patients participated in ongoing studies at the
psychiatric department of Rigshospitalet, University of
Copenhagen, Denmark. Individuals meeting the inclu-
sion criteria and none of the exclusion criteria are enrolled
in the trial (Appendix 1). The exclusion criteria were cho-
sen partly for safety reasons and partly to decrease the risk
of results being confounded by factors known to substan-
tially affect the HPA-axis, thus interfering the primary out-
come measure. Women taking birth control pills were
instructed to discontinue these 6 weeks prior to entering
the trial. All women were carefully instructed to use dou-
ble barrier birth control methods and pregnancy tests
were performed both before and after the intervention.
Interventions
The participants are randomized to receive either escitalo-
pram or placebo by oral administration as a single dose of
10 mg each evening as self-medication at home for four
weeks. On completion of four weeks of double-blind
intervention (or early discontinuation from the trial) par-
ticipants entered a five-day blinded down-titration period
to nil medication. Escitalopram 10 mg was selected
because of its specific serotonergic selectivity [33] and
because of the favourable adverse reaction profile [34],
thus facilitating blinding. The dose of escitalopram 10 mg
for four weeks was estimated to have a sufficient effect,Page 3 of 11
(page number not for citation purposes)
Trials 2009, 10:66 http://www.trialsjournal.com/content/10/1/66
Page 4 of 11
(page number not for citation purposes)
Flowchart for The Agenda Trialigure 1
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Trials 2009, 10:66 http://www.trialsjournal.com/content/10/1/66since effect on depressive symptoms in patients with a
major depression is observed within one to four weeks as
compared with placebo [34]. The validity of the results
depends on a high compliance and high completion in
the trial. This was sought obtained by weekly telephone
control calls to the enrolled participants to insure adher-
ence to the protocol and to record adverse events. Escita-
lopram and placebo tablets were identical in appearance,
colour, smell, and solubility allowing for blinding of
treatment assignment. H. Lundbeck A/S provided identi-
cally appearing blister packages containing escitalopram
or placebo. An independent pharmacist then packed,
sealed and numbered the drug packages according to a
randomization list provided and concealed by the Copen-
hagen Trial Unit (CTU), Centre for Clinical Intervention
Research, Rigshospitalet.
Randomization
Randomization into one of the two intervention groups is
done immediately after it has been established that the
participant fulfils all the inclusion criteria and none of the
exclusion criteria. Randomization is stratified by age (18
– 31 years and 32 – 60 years) and sex in order to get an
equal distribution in the intervention groups, knowing
that the response to the DEX-CRH test is sensitive to these
factors. Participants are randomized in a 1-to-1 ratio to
receive escitalopram 10 mg or placebo. The Copenhagen
Trial Unit (CTU), Centre for Clinical Intervention
Research, Rigshospitalet performs the centralised rand-
omization, and only the IT Manager of the CTU will know
the block size used for stratification. The sponsor-investi-
gator (UK) provides information of the participants to the
CTU during the entry assessment as soon as participation
in the study has been decided. CTU performs the compu-
ter-generated randomization to ensure adequate alloca-
tion concealment and adequate generation of the
allocation sequence [35]. The number of the allocated
treatment is communicated to UK, both by phone and
email.
Blinding
All study personnel and participants are blinded to the
packaging of the study drug, and blinding is maintained
throughout monitoring, follow-up, data management,
assessment of outcomes and data analyses. The randomi-
zation code will not be broken until all the data has been
analysed and conclusions drawn. At the assessment after
four weeks intervention, every participant, the sponsor-
investigator (UK), and the neuropsychological testers will
make a guess as to which intervention the participant has
received. When the trial is finished, inter-rater reliability
between the actual intervention and the guesses will be
estimated to assess the degree to which blinding has been
successful.
Outcome assessments
Outcomes are assessed at entry and after four weeks inter-
vention by assessors who are all blinded to the randomi-
zation group.
Depression has a wide range of possible features that can
be measured and tested as possible endophenotypes [36].
Since no prior trial has investigated the effect of SSRI on
healthy first-degree relatives of patients with depression,
we have chosen to include many outcomes since the
nature of this trial is predominantly exploratory, i.e.,
hypothesis generating, and only partly hypothesis testing.
When available, previously developed and validated
scales and instruments were used in order to facilitate
appropriate comparisons with data obtained in previous
studies.
Primary outcome
During selection of the primary outcome, it was stressed
that the outcome should be objective and of clinical
importance. Further, blinding should be possible at all
levels of assessment and analyses. The measurement of
change in plasma cortisol in the DEX-CRH test from entry
before to four weeks during intervention fulfils these cri-
teria. Plasma cortisol will be estimated as the total area
under the curve (AUC-total) from administration of CRH
at 15.00 hours to the last plasma cortisol measure at 18.00
hours. The DEX-CRH test is performed according to inter-
national standards with a few minor modifications [9];
thus plasma cortisol, plasma ACTH and salivary cortisol
are measured at the same time points.
Secondary outcomes
Secondary outcomes include changes in scores from base-
line to four weeks on: 1) cognitive functions are measured
with a broad battery of neuropsychological tests with rel-
evance in relation to depression, evaluating memory,
attention, visuomotor speed, visuo-constructional abili-
ties, decision making, logical thinking, executive func-
tions, verbal fluency, social and moral cognition,
recognition of emotions and emotional intelligence [37-
54], 2) neuroticism as measured by the NEO-PI-R [19]
and EPQ [18].
Tertiary outcomes
Tertiary outcomes include changes in scores from baseline
to four weeks on: 1) mood as measured by the Hamilton
rating scale for depression (HAM-D17) [55] and the Ham-
ilton rating scale for anxiety (HAM-A14 [56], 2) partici-
pants subjective perception of pain on a visual analogue
scale modified from Klepstad [57], 3) sleep on a visual
analogue scale for sleep quality, sleep items from the
HAMD-17 and supplementary questions on sleep charac-
teristics, 4) aggression by The Buss-Perry Aggression Ques-Page 5 of 11
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Depression Inventory (BDI-21) [59], 6) quality of life by
the WHO Quality of Life questionnaire [60], 7) a global
measure of stress by the Cohen Perceived Stress Scale [61],
and 8) salivary cortisol assessed by Salivettes during an
ordinary day in the participants usual environment at the
following time points: awakening, awakening + 15 min.,
awakening + 30 min., awakening + 45 min., awakening +
60 min., 12:00, 18:00 and at 23:00 [62]. Further, side-
effects are assessed at four weeks by the UKU Side Effect
Rating Scale [63].
Genotyping
Blood samples are stored in a bio bank for further analy-
ses. Among others we intend to genotype for the 5-
HTTLPR-short/long-promoter variant, and the catechol-
O-methyltransferase (COMT), and to test whether these
genotypes will be associated with the response to escitalo-
pram on the potential endophenotypes for depression.
Further, messenger RNA for the glucocorticoid receptor
will be analysed and associated to the effect of escitalo-
pram.
Assessments
Participants are subjected to almost identical sequences of
assessments at entry and after four weeks of intervention
(Appendix 2). The first part of the assessment is a tele-
phone interview, and the individuals who are not
excluded at that time point, are scheduled to meet at the
clinic at two different days before and following four
weeks of intervention with escitalopram or placebo. At the
first day of examination the participants are interviewed
to evaluate fulfilment of inclusion and exclusion criteria
including the Schedules for Clinical Assessment in Neu-
ropsychiatry (SCAN) [64] and various socio-demograph-
ics.
Sample size
A high-risk study performed by Modell et al. [9] found
that healthy high-risk probands of patients with a diagno-
sis of depression examined by the DEX-CRH test present
with a cortisol AUC-total (mean ± SEM) of 15,064 ± 3,947
nmol × min/L. Further, Modell et al reported that cortisol
AUC-total (mean ± SEM) in healthy individuals with no
family history of depression was 7,773 ± 1,071 nmol ×
min/L. A clinically relevant effect of escitalopram on the
cortisol AUC-total (mean ± SEM) was thus estimated to be
the difference in cortisol AUC-total (mean ± SEM) of
high-risk probands of patients with the diagnosis of
depression and that of healthy individuals with no family
history of depression. Accordingly, the relevant difference
we aim to detect or reject is 15,064 – 7,773 = 7,291 nmol
× min/L. Given a standard deviation (SD) = SEM × √14 =
3,947 × 3.7 = 14,768 nmol × min/L provides a power of
the trial at a minimum of 60% (1 - β = 0.60), β being the
risk of overlooking a difference in the cortisol AUC-total.
However, the power in the trial may be higher, consider-
ing the use of analysis of covariance (ANCOVA) of the
change from entry to after four weeks of intervention in
AUC total during the DEX-CRH test. Based on these calcu-
lations we aim for a full data set of 80 participants to be
able to conclude in relation to the primary outcome meas-
ure.
Statistical methods
All data analyses will be carried out according to a pre-
established analysis plan. The main null-hypothesis to be
tested is that there is no difference between the two inter-
vention arms with regard to the plasma cortisol AUC-total
in the DEX-CRH test. All randomized participants will be
analysed, including those with missing data on AUC.
Statistical analyses will be performed using ANCOVA
[65]. Thus, the outcomes will be analysed as the difference
for the individual participant's before and after the inter-
vention, firstly unadjusted and then adjusted for a
number of variables, if they present with a p-value < 0.1 in
the univariate analyses [66], see Table 1. Initially the drug
level measured in each participant will not be included in
the models in order as to keep the analysers blinded. Later
on analyses for the effect of drug-level will be performed
along with other significant covariates in the multivariate
model. Separate analyses will be performed in a log linear
model of the changes in the primary outcome as com-
pared to the secondary and tertiary outcomes.
In the case of missing data according to the primary out-
come, analyses will be performed both on complete data
sets, as well as data sets on all participants completed by
multiple imputation (MI) of missing data by MI-analysis
(SASS version 9.1 or NORM version 1) based on age, sex,
body mass index, HAMD, neuroticism before and after
the intervention, years of education, and AUC-total for
cortisol, and ACTH and salivary cortisol before and after
the intervention. In the case of discrepancy between these
results, the result from the MI procedure is regarded as the
result in the trial. P < 0.05 will be regarded as statistically
significant.
Data management
All the data of each participant is kept in a Case Record
File, which fulfils the Danish law for medical doctors'
obligation to keep patient records. In order to maintain
blinding, the result of serum escitalopram concentration
at end of the intervention is sent to the CTU, that keeps it
in a locked safety box until the practical part and the data
analyses of the trial are finished. Participants are not reg-
istered in The Danish Psychiatric Central Research Regis-
ter or in any local hospital registers.Page 6 of 11
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Procedures for breaking the code for randomization has
been established for the case of severe adverse reactions,
which can be related to the intervention or if a serious
adverse events occur. It is the decision of UK and LK to
request emergency breaks, and the CTU can be contacted
at any time regarding the practical procedure. The partici-
pants can at all times reach UK by mobile phone. An inde-
pendent data monitoring and safety committee has been
established to further ensure the safety of the participants,
should the need for considering early stopping occur.
Results
Current trial status
Enrolment started July 2007 and is ongoing until July
2009. Status in May 2009 is that 390 eligible persons have
been screened and that 77 of these have been randomized
(Figure 1) and the dataset is complete for 64 participants
regarding the primary outcome measure.
Ethical considerations
The regional ethics committee for the greater Copenhagen
area has approved the protocol (H-KF-307413) as has The
Danish Data Protection Agency (2006-41-6737) and The
Danish Medicines Agency (2612-3162). The trial has the
EudraCT number 2006-001750-28 and is registered at
ClinicalTrials.gov as NCT 00386841. Both positive, neu-
tral, and negative findings from the trial will be published
in accordance with the CONSORT guidelines [67]. The
trial is conducted and monitored in accordance with the
International Conference on Harmonization for Good
Clinical Practice guidelines [66] and the Declaration of
Helsinki 2002 http://www.wma.net/e/policy/b3.htm.
Information about the trial is presented to potential par-
ticipants both verbally and in written form in quiet sur-
roundings, and the participants were given permission to
bring a relative or friend. It is made clear that participation
is voluntary and that the participant can withdraw the
given consent at any time without consequence for future
treatment possibilities. Participants receive a copy of their
rights. All participating healthy volunteers sign a written
informed consent. The participants are paid up to 9,000
Danish crowns for full participation (equal to about one
weeks pay) and are further compensated for any travel
expenses. When the randomization code is broken the
participants will receive a letter with information on
whether they received escitalopram or placebo and the
major results of the trial.
Discussion
The AGENDA trial is the first trial investigating whether an
antidepressant has an effect on potential endophenotypes
in healthy first-degree relatives of patients with a diagno-
sis of depression. This represents a new strategy to validate
potential endophenotypes for depression, which may cast
light on the pathophysiology of depression. The trial is
fully investigator initiated and controlled to secure unbi-
ased assessment of the effect of escitalopram on endophe-
notypes of healthy first-degree relatives of patients with
depression. The AGENDA trial has received non-restricted
grants from non-profit and for-profit organizations.
Table 1: Covariates in the statistical models for the AGENDA trial.
Outcome Primary outcome:








Age x x x x
Gender x x x x
HAMD, entry x x x
Body Mass Index, entry x




Years of education x
Drug-level x x x xPage 7 of 11
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Further knowledge of endophenotypes may increase the
validity of the diagnosis of depression in the future and
may eventually improve our possibilities to reclassify
depression. The principle of testing the effect of a psycho-
tropic drug on possible endophenotypes for a given disor-
der could be used to test putative endophenotypes for
other disorders as well.
Further outcome assessments
We plan to assess the effect of escitalopram versus placebo
on a number of other outcomes in healthy participants
with a family history of depression. These assessments
include:
A: Investigation of the association between inflammation
and depression. A flow-cytometric profile with focus on
activated and non-activated t-cell subsets measured before
and after intervention. Furthermore inflammatory varia-
bles and proinflammatory genepolymorphisms are meas-
ured.
B. Magnetic Resonance Imaging (MRI) of hippocampus
volume. Studies of patients with unipolar depression sug-
gest a decreased volume of hippocampus in MR scans
[68]. Decreased volume of hippocampus is a possible
endophenotype for depression and the effect of SSRI on
hippocampal volume has not been established in healthy
individuals with a family history of depression. Func-
tional MRI including Face Emotion – Gender Discrimina-
tion Task [69] and Flanker Go-No go Risk paradigm [70]
is conducted in a subpopulation of participants in the
AGENDA trial.
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Appendices
Appendix 1. Criteria for inclusion and exclusion in the 
AGENDA trial
Inclusion criteria
• Healthy individual of both sexes. Women should
preferable be in day 1–13 of her menstrual cycle at the
time of randomization.
• Offspring or sibling of an ethnic Dane, with a history
of psychiatric in- or outpatient care with the diagnosis
of depression and who later had the diagnosis verified
in a SCAN interview at the Department of Psychiatry
Rigshospitalet, Denmark 2004–2009.
• Aged 18 – 60 years.
• Born in Denmark.
• European parents and grandparents.
• Able and willing to sign informed consent.
Exclusion criteria
• Somatical illness or other handicap, which make
participation in the trial impossible.
• Daily intake of drugs interfering with corticosteroids
or escitalopram, including birth control pills or any
kind of corticosteroids.
• Hypersensitivity to escitalopram, dexamethasone, or
human corticotrophin-releasing hormone.
• Former medical or psychological treatment for dis-
eases in the affective or schizophrenic spectrum.
• Abuse of alcohol or psychotropic medication.
• For women: pregnancy or breastfeeding.
Appendix 2. Assessments of prognostic factors and 
outcome measures in the AGENDA trial
Basic information
Socio-demographics, family history of psychiatric illness,
Kendler's questionnaire for lifetime events in a brief Dan-
ish version [71], Schedules for Clinical Assessment in
Neuropsychiatry, version 2.1[64], The Structured Clinical
Interview for DSM – IV Axis II Personality Disorders [72],
birth weight, height, current weight, waist-hip ratio andPage 8 of 11
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pregnancy test is performed.
At entry and at four weeks of intervention the following variables are 
assessed
HPA-Axis
The Combined Dexamethasone Corticotrophine-releas-
ing Hormone Test (DEX-CRH) salivary cortisol, plasma
cortisol and plasma-ACTH are measured every 15 minutes
from 14:00 – 18:00 hours [9].
Cognition
The Danish Adult Reading Test [37], Familiar faces [38],
Trail Making A and B [39], Stroop test [74], Boston nam-
ing [40], Block Designs [41], Cambridge Cognitive Exam-
ination [43], Rey Auditory Verbal Learning Test [44], Rey-
Osterrieth Complex Figure [45], verbal fluency for ani-
mals and letter "s" [46], Symbol Digit Modalities Test
[47], Iowa Gambling Task [48], Letter-number sequenc-
ing [49], recognition of facial emotions [54], moral judge-
ment [51,52], Mayer-Salovey-Caruso Emotional
Intelligence Test [53].
Personality
Eysenck Personality Questionnaire [18] and NEO Person-
ality Inventory revised, computer version [19].
Rating scales of mood
Hamilton Depression Scale 17-items [55] and Hamilton
Anxiety Scale, 14-items [56].
Depressive symptoms, quality of life, perceived stress, subjective 
evaluations of aggression, sleep and pain
Buss-Perry Aggression Questionnaire [58], Beck Depres-
sion Inventory, 42-items [59], Side Effect Self Rating Scale
by UKU-SERS-Pat [63], WHO Quality of Life [75],
Cohen's Perceived Stress Scale [61] and Klepstad Visual
Analogue Scale for pain, modified [57]. Sleep is evaluated
by Hamilton Depression Scale and additional questions
of number of night sleep hours, subjective quality of sleep
on a visual analogue scale and number of interruptions of
sleep.
Salivary cortisol
Saliva samples by Salivettes for measurements of cortisol
are obtained at the clinic and during a day in the partici-
pant's usual environment.
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